Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPSTER-Pilot: Rivaroxaban + ASA after Hip Fracture Surgery
NCT07228663Phase 3Not yet recruiting
- Sponsor
- McMaster University
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of rivaroxaban, aspirin in cardiovascular disease (CVD), venous thromboembolism (VTE), sponsored by McMaster University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
rivaroxabanaspirin
03
Conditions
cardiovascular disease (CVD)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07228663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228663.